Life Sciences IP Focus 8th edition (September 2010)

Main

Editorial

Interview: How to manage an in-house IP team

Understand the economics behind licensing deals

What the EPO’s rule changes mean for life science applicants

Case law clarifies patent questions

Australia ponders the patentability of genes

Are patents for orphan drugs crucial?

Japan moves to protect drug innovators

Mexico gets ready to approve biocomparable drugs

Lessons from the Valcyte patent battle

Tap into Japan’s demand for functional foods

Inaugural revocation proceedings in Singapore

The progression of patentability

Editorial

Features / Articles

Sponsored